Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

被引：7
|
作者：
Jerkeman, Mats
Kolstad, Arne
Niemann, Carsten Utoft
Groenbaek, Kirsten
Hutchings, Martin
Pasanen, Annika
Ekberg, Sara
Wader, Karin Fahl
Glimelius, Ingrid
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [32] Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
    Trneny, Marek
    Lamy, Thierry
    Walewski, Jan
    Belada, David
    Mayer, Jiri
    Radford, John
    Jurczak, Wojciech
    Morschhauser, Franck
    Alexeeva, Julia
    Rule, Simon
    Afanasyev, Boris
    Kaplanov, Kamil
    Thyss, Antoine
    Kuzmin, Alexej
    Voloshin, Sergey
    Kuliczkowski, Kazimierz
    Giza, Agnieszka
    Milpied, Noel
    Stelitano, Caterina
    Marks, Reinhard
    Truemper, Lorenz
    Biyukov, Tsvetan
    Patturajan, Meera
    Bravo, Marie-Laure Casadebaig
    Arcaini, Luca
    LANCET ONCOLOGY, 2016, 17 (03): : 319 - 331
  • [33] Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
    Duehrsen, Ulrich
    Tometten, Mareike
    Kroschinsky, Frank
    Ganser, Arnold
    Ibach, Stefan
    Bertram, Stefanie
    Huettmann, Andreas
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [34] Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
    Ulrich Dührsen
    Mareike Tometten
    Frank Kroschinsky
    Arnold Ganser
    Stefan Ibach
    Stefanie Bertram
    Andreas Hüttmann
    Blood Cancer Journal, 11
  • [35] A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.
    Mehta-Shah, Neha
    Lunning, Matthew Alexander
    Boruchov, Adam M.
    Ruan, Jia
    Nair, Sumithra
    Lynch, Peggy
    Byrne, Regina
    Moskowitz, Alison J.
    Matasar, Matthew J.
    Gerecitano, John F.
    Hamlin, Paul A.
    Leonard, John
    Moskowitz, Craig H.
    Myskowski, Patricia L.
    Querfeld, Christiane
    Nolan, Patrick
    Palomba, Maria Lia
    Straus, David J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] A phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Delpassand, E
    McLaughlin, P
    Romaguera, J
    Wang, M
    BLOOD, 2003, 102 (11) : 406A - 406A
  • [37] QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL
    Rule, S.
    Arcaini, L.
    Walewski, J.
    Skotnicki, A.
    Belada, D.
    Mayer, J.
    Alexeeva, J.
    Afanasyev, B.
    Kuzmin, A.
    Jurczak, W.
    Kaplanov, K.
    Voloshin, S.
    Radford, J.
    Le Gouill, S.
    Biyukov, T.
    Patturajan, M.
    Casadebaig-Bravo, M. L.
    Mahmoud, D.
    Hu, X. H.
    Trneny, M.
    HAEMATOLOGICA, 2015, 100 : 147 - 147
  • [38] A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
    Blum, Kristie A.
    Baiocchi, Robert A.
    Alinari, Lapo
    Lin, Thomas S.
    Porcu, Pierluigi
    Jones, Jeffrey
    Flynn, Joseph
    Hicks, William
    Lucas, Margaret S.
    Wei, Lai
    Johnston, Jeffrey S.
    Byrd, John C.
    BLOOD, 2008, 112 (11) : 1049 - 1050
  • [39] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
    Flinn, Ian W.
    Mainwaring, Mark
    Peacock, Nancy
    Shipley, Dianna
    Arrowsmith, Edward
    Savona, Michael R.
    Hainsworth, John D.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [40] Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
    Jerkeman, Mats
    Eskelund, Christian Winther
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Toldbod, Helle
    Pedersen, Lone Bredo
    Niemann, Carsten Utoft
    Dahl, Christina
    Kuitunen, Hanne
    Geisler, Christian H.
    Gronbaek, Kirsten
    Kolstad, Arne
    LANCET HAEMATOLOGY, 2018, 5 (03): : E109 - E116
12345